Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics and enlists all their major and minor projects

The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Altor BioScience Corp

arGEN-X BV

Ariad Pharmaceuticals Inc

Array BioPharma Inc

Ascentage Pharma Group Corp Ltd

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bio-Path Holdings Inc

BioLineRx Ltd

BioSight Ltd

Boston Biomedical Inc

Bristol-Myers Squibb Co

Cantargia AB

Celgene Corp

Cellectis SA

Cielo Therapeutics Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

Eisai Co Ltd

Epizyme Inc

Galena Biopharma Inc

Gamida Cell Ltd

GlaxoSmithKline Plc

GlycoMimetics Inc

GT Biopharma Inc

Hovione FarmaCiencia SA

Hybrigenics SA

IGF Oncology LLC

Ilyang Pharmaceutical Co Ltd

Immune Pharmaceuticals Inc

Incyte Corp

Johnson & Johnson

Juno Therapeutics Inc

JW Pharmaceutical Corp

Karyopharm Therapeutics Inc

LG Chem Ltd

Lixte Biotechnology Holdings Inc

Millennium Pharmaceuticals Inc

Natco Pharma Ltd

Novartis AG

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

PharmaEssentia Corp

Phylogica Ltd

Sellas Life Sciences Group Ltd

Selvita SA

Shenogen Pharma Group Ltd

SignalChem Lifesciences Corp

Stemline Therapeutics Inc

Sun Pharma Advanced Research Company Ltd

Synactix Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Teva Pharmaceutical Industries Ltd

TRACON Pharmaceuticals Inc

Xencor Inc

Xspray Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 7

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development 8

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 23

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 37

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles 67

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 492

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 497

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 498

Appendix 512

List of Tables

List of Tables

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2017 19

Number of Products under Development by Companies, H2 2017 21

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 24

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 25

Number of Products under Development by Universities/Institutes, H2 2017 26

Products under Development by Companies, H2 2017 28

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 29

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 30

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 31

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 32

Products under Development by Universities/Institutes, H2 2017 33

Number of Products by Stage and Target, H2 2017 35

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 36

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 37

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 38

Number of Products by Stage and Mechanism of Action, H2 2017 40

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 41

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 42

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 43

Number of Products by Stage and Route of Administration, H2 2017 45

Number of Products by Stage and Molecule Type, H2 2017 47

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by AbbVie Inc, H2 2017 48

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Altor BioScience Corp, H2 2017 49

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by arGEN-X BV, H2 2017 49

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Ariad Pharmaceuticals Inc, H2 2017 50

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Array BioPharma Inc, H2 2017 50

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 50

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Astex Pharmaceuticals Inc, H2 2017 51

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by AstraZeneca Plc, H2 2017 51

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Atara Biotherapeutics Inc, H2 2017 52

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Bio-Path Holdings Inc, H2 2017 52

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by BioLineRx Ltd, H2 2017 53

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by BioSight Ltd, H2 2017 53

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Boston Biomedical Inc, H2 2017 53

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Bristol-Myers Squibb Co, H2 2017 54

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Cantargia AB, H2 2017 54

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Celgene Corp, H2 2017 55

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Cellectis SA, H2 2017 56

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Cielo Therapeutics Inc, H2 2017 56

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 56

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 57

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Eisai Co Ltd, H2 2017 57

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Epizyme Inc, H2 2017 58

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Galena Biopharma Inc, H2 2017 58

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Gamida Cell Ltd, H2 2017 59

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by GlaxoSmithKline Plc, H2 2017 59

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by GlycoMimetics Inc, H2 2017 60

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by GT Biopharma Inc, H2 2017 60

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Hovione FarmaCiencia SA, H2 2017 60

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Hybrigenics SA, H2 2017 61

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by IGF Oncology LLC, H2 2017 61

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2017 62

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Immune Pharmaceuticals Inc, H2 2017 62

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Incyte Corp, H2 2017 63

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Johnson & Johnson, H2 2017 63

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Juno Therapeutics Inc, H2 2017 64

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by JW Pharmaceutical Corp, H2 2017 64

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Karyopharm Therapeutics Inc, H2 2017 65

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by LG Chem Ltd, H2 2017 65

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 66

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 66

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Natco Pharma Ltd, H2 2017 67

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Novartis AG, H2 2017 68

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by OncoTherapy Science Inc, H2 2017 68

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 69

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Pfizer Inc, H2 2017 69

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Pharma Mar SA, H2 2017 70

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by PharmaEssentia Corp, H2 2017 70

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Phylogica Ltd, H2 2017 71

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Sellas Life Sciences Group Ltd, H2 2017 71

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Selvita SA, H2 2017 72

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Shenogen Pharma Group Ltd, H2 2017 72

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by SignalChem Lifesciences Corp, H2 2017 72

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Stemline Therapeutics Inc, H2 2017 73

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 74

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Synactix Pharmaceuticals Inc, H2 2017 74

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Syndax Pharmaceuticals Inc, H2 2017 75

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 75

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 76

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Xencor Inc, H2 2017 76

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline by Xspray Pharma AB, H2 2017 77

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H2 2017 503

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H2 2017 (Contd..1), H2 2017 504

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H2 2017 (Contd..2), H2 2017 505

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H2 2017 (Contd..3), H2 2017 506

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant Projects, H2 2017 (Contd..4), H2 2017 507

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Discontinued Products, H2 2017 508

List of Figures

List of Figures

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2017 19

Number of Products under Development by Companies, H2 2017 20

Number of Products under Development by Universities/Institutes, H2 2017 26

Number of Products by Top 10 Targets, H2 2017 34

Number of Products by Stage and Top 10 Targets, H2 2017 34

Number of Products by Top 10 Mechanism of Actions, H2 2017 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 39

Number of Products by Routes of Administration, H2 2017 44

Number of Products by Stage and Routes of Administration, H2 2017 44

Number of Products by Top 10 Molecule Types, H2 2017 46

Number of Products by Stage and Top 10 Molecule Types, H2 2017 46

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports